Legato Capital Management LLC raised its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 140.7% in the 4th quarter, Holdings Channel reports. The firm owned 26,076 shares of the company’s stock after purchasing an additional 15,241 shares during the quarter. Legato Capital Management LLC’s holdings in Guardant Health were worth $2,663,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Alyeska Investment Group L.P. bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $114,421,000. Franklin Resources Inc. boosted its holdings in Guardant Health by 26.1% in the third quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after acquiring an additional 606,368 shares during the last quarter. Baillie Gifford & Co. increased its position in Guardant Health by 6.6% during the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock valued at $320,378,000 after purchasing an additional 317,906 shares during the period. Qube Research & Technologies Ltd increased its position in Guardant Health by 124.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 570,095 shares of the company’s stock valued at $35,620,000 after purchasing an additional 315,896 shares during the period. Finally, Federated Hermes Inc. raised its holdings in Guardant Health by 21.2% during the 3rd quarter. Federated Hermes Inc. now owns 1,776,369 shares of the company’s stock worth $110,988,000 after purchasing an additional 310,931 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, CEO Amirali Talasaz sold 210,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the sale, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the completion of the transaction, the chief financial officer owned 43,601 shares in the company, valued at $3,795,031.04. This represents a 6.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 296,838 shares of company stock worth $31,878,906 in the last 90 days. Company insiders own 5.60% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Guardant Health
Guardant Health Trading Up 0.8%
GH opened at $118.95 on Friday. Guardant Health, Inc. has a 1-year low of $36.36 and a 1-year high of $121.01. The company has a market cap of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48. The company’s fifty day moving average price is $91.15 and its two-hundred day moving average price is $98.94.
Guardant Health (NASDAQ:GH – Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. Guardant Health’s revenue was up 39.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.62) EPS. As a group, equities analysts forecast that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.
Guardant Health Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
- Five stocks we like better than Guardant Health
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
